Looking back on this year’s milestones, we extend our heartfelt gratitude to all our clients, partners, and colleagues for their continued dedication to moving healthcare forward. We are wishing you a season of well-deserved rest and celebration. May the upcoming year bring breakthroughs, successful outcomes, and continued progress in improving lives through innovative research and skillful application.

Happy Holidays, and a prosperous New Year from all of us at GCT!

Let us share a selection of our 2023 highlights with you:

Expanding our Offices

GCT recently opened a new branch in China. We are excited to take on new projects in the Asian market, as China offers a large and highly diverse pool of patients, increasingly advanced facilities, and experienced investigators.

We have also expanded our Georgian office in Tbilisi – our team in Georgia has been working tirelessly to bring new clinical trials to the country. The new office will provide a solid base for further growth and success.

Expanding our Pharmacovigilance Team

Early this year we also made a valuable addition to our Pharmacovigilance team – Dr. Olena Datsenko brings more than 20 years of experience and extensive knowledge of the safety requirements in clinical trials.

Adding to our Study Portfolio

We continue to take on new and exciting projects – amongst other studies, we are supporting an international Phase III Hematology Clinical Trial in 20 sites. We are also overseeing the outcomes of our existing trials – phase II Dravet Syndrome, Phase II study for the treatment of chronic limb-threatening ischemia, which doubled in the number of sites in the US in the past 6 months, and a Respiratory Pediatric Phase IV Clinical Trial.

Audit services

GCT takes pride in our Quality Assurance department, as this year we were hired by repeat clients to perform a series of audits. This only goes to show the professionalism and responsible attitude GCT puts towards the execution of the clinical studies we handle, as well as the dedication we have for our clients. Across all audits, GCT’s QA professionals upheld the highest standards, evaluating adherence to study protocols, Standard Operating Procedures (SOPs), GCP guidelines, and International Council for Harmonisation (ICH) guidelines.

GCT also successfully passed a site audit in Romania for the Respiratory Pediatric Phase IV Clinical Trial with no major findings.



Keeping Up to Date with Pharma and Biotech Community

We enjoyed participating in this year’s Pharma and Biotech events. Not limiting ourselves to one region we took part in various conferences in the USA, EU, EAEU, and Asia. GCT is always happy to meet with familiar faces, but also to make new connections, and to share industry knowledge.

To name a few, we were excited to attend AAIC, Clinical Trials in Rare Diseases 2023, CTSS, DIA 2023, ECNP, Clinical Trials Forum in Kyiv, 14th International Eurasian Pharmaceutical Forum.

We look forward to more exciting projects and fruitful partnerships in 2024.

Stay tuned and see where the next year takes us!

Happy Holidays!